NCT03950804View on ClinicalTrials.gov

Transcriptome and Metabolic Analyses of CHAPLE Disease

UnknownOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

September 15, 2019

Study Completion Date

June 15, 2020

Conditions
CD55 - Cluster of Differentiation Antigen 55 DeficiencyPrimary Intestinal LymphangiectasisProtein-Losing EnteropathiesComplement Regulatory Factor Defect
Interventions
DRUG

Eculizumab Injection

Patients receive eculizumab as deemed necessary by the primary physician

Trial Locations (1)

Unknown

RECRUITING

Marmara University, Istanbul

Sponsors

Lead Sponsor

Marmara University
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Marmara University

OTHER